ABSTRACT
Curcumin is one of the commonly used dietary supplements with wide pharmacological activities but the main hindrance in the commercial exploitation of curcumin is the issue with its solubility and stability. Hence, the aim of the present study was to formulate curcumin silver nanoparticles (CSNP) by chemical reduction method and to evaluate its solubility, stability as well as diffusion properties. The CSNP was combined with potent anti-inflammatory drug Diclofenac sodium (DS) to prepare gels (F1-F7), cream (F8) and ointment (F9). The DS-CSNP was subjected to in vitro and in vivo anti-inflammatory activity by albumin denaturation method and carrageenan-induced paw oedema method using albino rats, respectively. Results of the present study revealed that CSNP possess good solution stability in different pH solutions compared to pure curcumin, and the particle size as well as zeta potential were found to be 115 nm and - 5.69 mV, respectively for CSNP. Based on the results of in vitro release study and in vitro anti-inflammatory activity, formulation F4, F5, F9 and marketed product were subjected for in vivo anti-inflammatory activity. Among the three formulations, formulation F9 showed the maximum inhibition of the oedema (82.25%) at the end of 90 min followed by F5 and F4. In addition, formulations F4, F5, and F9 exhibited better in vivo anti-inflammatory activity in comparison with the marketed product which might be due to synergistic effect of the combination of curcumin silver nanoparticles and DS. In conclusion, CSNP-incorporated DS semisolid preparations were stable and can yield promising anti-inflammatory activity compared to marketed formulation; hence, these formulation can be exploited commercially in the preparation of anti-inflammatory dosage forms.
ABSTRACT
AIM AND BACKGROUND: The novelty of the present study was to control the release profile of matrix tablets of losartan potassium prepared by using different concentrations of chitosan and trisodium citrate as cross-linking agent with combination of various release retardant polymers. MATERIALS AND METHODS: Twelve formulations were prepared using HPMC K100M, carbopol 934P, and xanthan gum as polymers. Matrix tablets were prepared by wet granulation technique. The granules were subjected to precompression parameters such as angle of repose, loose bulk density, tapped bulk density, compressibility index. Tablets were evaluated for weight variation, hardness, drug content, in-vitro dissolution, stability studies, respectively. Drug -polymer compatibility studies were determined by FTIR spectroscopy. Further stability studies were carried out for 3months in accelerated conditions at 40°C and 75%RH. The granules of all formulations exhibited good flow and compressibility. In-vitro dissolution studies were carried out for 24 h using 0.1 N HCl for the first 2 h and pH 6.8 phosphate buffers for the remaining 22h. RESULTS: It was found that among the 12 formulations F11 and F12 showed good dissolution profile to control the drug release. The release data was fitted to various mathematical models such as, Higuchi, Korsmeyer, first-order, and zero-order to evaluate the kinetics and the drug release. The drug release follows zero-order kinetics and the mechanism was found to be diffusion controlled and Case II transport. FT-IR spectroscopic studies revealed no interaction between drug and polymer. The stability studies indicated that F11 and F12 formulations were stable for 3months. CONCLUSION: The above results concluded that by combining different classes of polymers an acceptable release profile can be obtained in the fluctuating in vivo environment.
